Use this medication on the skin only. Do not use it on the face, groin, or underarms unless directed to do so by your doctor. Wash and dry your hands before using. Clean and dry the affected area.

Clobetasol propionate 0.05%; crm; oint; gel; soln for scalp application. Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or ...

Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose ...

The information provided on this page is intended to serve as a comprehensive resource and should not be a substitute to professional medical advice. If you have concerns it is always best to ...

EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion ...

The patient was initially treated with desoximetasone 0.25% ointment b.i.d. and then clobetasol propionate 0.05% cream b.i.d. Other medications included atorvastatin and conjugated estrogen.

Class I corticosteroids, (e.g., clobetasol propionate 0.05% cream or ointment) may be used, but can lead to cutaneous atrophy if applied for prolonged periods. They must not be used on the face or ...

Phimosis is a condition in which the foreskin of the penis (prepuce) cannot be pulled back over the head of the penis (glans). Phimosis can cause the ballooning of the foreskin when urinating ...

“With Mydcombi available for pre-surgical pupil dilation, clobetasol available for post-surgical pain and inflammation, and Avenova Antimicrobial Lid and Lash Solution used both pre- and post ...

Clobetasol propionate 0.05%; crm. Treat infection if present; discontinue if infection persists or worsens. Do not use near eyes, or on diaper dermatitis or pre-existing skin atrophy. Do not use ...

NEW YORK, April 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products. Phase IV study of ...

Eyenovia licensed clobetasol propionate ophthalmic suspension 0.05%, which leverages APNT technology, from Formosa in August 2023, and clobetasol was subsequently approved by the U.S. Food and ...